RPRX Insider Trading
Insider Ownership Percentage: 18.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Royalty Pharma Share Price & Price History
Current Price: $32.75
Price Change: ▲ Price Increase of +0.205 (0.63%)
As of 04/29/2025 04:59 PM ET
Royalty Pharma Insider Trading History
Royalty Pharma Institutional Trading History
Data available starting January 2016
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Read More on Royalty Pharma
Today's Range
Now: $32.75
52 Week Range
Now: $32.75
Volume
1,712,285 shs
Average Volume
3,257,220 shs
Market Capitalization
$18.88 billion
P/E Ratio
22.56
Dividend Yield
2.73%
Beta
0.5
Who are the company insiders with the largest holdings of Royalty Pharma?
Who are the major institutional investors of Royalty Pharma?
Royalty Pharma's top institutional investors include:
- New South Capital Management Inc. — 0.50%
- Bank of New York Mellon Corp — 0.25%
- Wedge Capital Management L L P NC — 0.18%
- Sumitomo Mitsui Trust Group Inc. — 0.15%
- Marathon Asset Management Ltd — 0.11%
- Robeco Institutional Asset Management B.V. — 0.11%
Learn More about top institutional investors of Royalty Pharma stock.
Which major investors are selling Royalty Pharma stock?
During the last quarter, RPRX stock was sold by these institutional investors:
- Sumitomo Mitsui Trust Group Inc.
- Marathon Asset Management Ltd
- Overbrook Management Corp
- New South Capital Management Inc.
- Manning & Napier Advisors LLC
- Bank of New York Mellon Corp
- Handelsbanken Fonder AB
- Paragon Capital Management Inc.
Which major investors are buying Royalty Pharma stock?
During the last quarter, RPRX stock was acquired by institutional investors including:
- Wedge Capital Management L L P NC
- Advisor Resource Council
- Moran Wealth Management LLC
- Robeco Institutional Asset Management B.V.
- GAMMA Investing LLC
- SG Americas Securities LLC
- Mirae Asset Global Investments Co. Ltd.
- Board of the Pension Protection Fund